Pediatric patients with AAV who undergo kidney transplantation have comparable survival to non-AAV kidney recipients.

As gene therapies advance toward indications with larger patient populations, adeno-associated virus (AAV) manufacturers are under growing pressure to deliver high-quality vectors at substantially ...

AskBio founder R. Jude Samulski talks about the evolution and future of AAV gene therapy following his company’s blockbuster acquisition by Bayer in 2020. R. Jude Samulski, PhD It is rare that a ...

PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, ...

While there is no cure for ANCA-associated vasculitis (AAV), treatment is usually very effective at bringing it under control and preventing life-threatening complications. This group of rare ...

Adeno-associated virus (AAV) vectors have become widely recognized as a fundamental tool in gene therapy, primarily due to their potential as a delivery system for the treatment of genetic disorders.

Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is a transmembrane receptor found on microglia, where it modulates cell activity and survival. In addition to membrane-associated TREM2, there ...